AMENDMENTS TO THE CLAIMS

Kindly amend the claims as follows:

1. (Canceled)

2. (Currently Amended) The vaccine according to ~~integrated viral complex of~~ claim 37, wherein said virion is ~~as are~~ DNA virion~~s~~.

3. (Currently Amended) The vaccine according to ~~integrated viral complex of~~ claim 2, wherein said DNA virion is~~s are~~ a double stranded DNA virion~~s~~.

4. (Currently Amended) The vaccine according to ~~integrated viral complex of~~ claim 3, wherein said virion ~~double stranded DNA virions belong to the~~ is a herpes virus~~es~~.

5. (Currently Amended) The vaccine according to ~~integrated viral complex of~~ claim 4, wherein said ~~herpes~~ virus is Marek's disease virus.

6. (Canceled)

7. (Currently Amended) The pharmaceutical composition according to ~~of~~ claim ~~7~~ 38, supplied as an article of manufacture including packaging material and instructions for use.

8. (Currently Amended) The pharmaceutical composition according to ~~of~~ claim ~~7~~ 38, wherein said vaccine comprises ~~virions are~~ double stranded DNA virions.

9. (Currently Amended) The pharmaceutical composition according to ~~of~~ claim ~~9~~ 8, wherein said double stranded DNA virions are ~~double stranded DNA virions~~ herpes viruses, especially Marek's disease viruses.

10. (Canceled)

11. (Canceled)

12. (Withdrawn) A method for producing integrated viral complexes, the method comprising:

(a) growing a population of individual cells in culture;

(b) infecting said individual cells belonging to said population with an aliquot of viable virions so that a desired viral yield is achieved;

(c) transferring said population of individual cells characterized by said desired viral yield to a storage medium containing a cyroprotectant;

(d) storing said population of individual cells characterized by said desired viral yield at a temperature in the range of (-) 30 to (+) 8 degrees centigrade.

13. (Withdrawn) The method of claim 12, wherein said infecting employ a viral preparation selected from the group consisting of a cell free preparation and a cell associated preparation.

14. (Withdrawn) The method of claim 12, wherein said cryoprotectant includes at least one material selected from the group consisting of glycerol, DMSO, and sugars.

15. (Withdrawn) The method of claim 12, wherein said desired viral yield is in the range of 0.001 to 1 PFU/cell.

16. (Withdrawn) The method of claim 12, wherein said temperature in the range of (+) 2 to (+) 8 degrees centigrade.

17. (Withdrawn) The method of claim 12, further comprising:

(e) passaging said individual cells belonging to said population with said desired viral yield as a means of increasing a size of said population.

18. (Withdrawn) The method of claim 12, further comprising:

(e) reducing a volume of said storage medium so that a desired number of cells per unit volume is achieved.

19. (Withdrawn) The method of claim 12, further comprising:

(e) drying said population of individual cells.

20. (Withdrawn) A method of producing a pharmaceutical composition for vaccination, the method comprising:

(a) growing a population of individual cells in culture;

(b) infecting said individual cells belonging to said population with an aliquot of viable virions so that a desired viral yield is achieved;

(c) transferring said population of individual cells characterized by said desired viral yield to a storage medium containing a cryoprotectant;

(d) dividing said population of individual cells characterized by said desired viral yield into dosage portions suited for vaccination of a specified number of subjects; and

(e) storing said dosage portions at a temperature in the range of (-) 30 to (+) 8 degrees centigrade.

21. (Withdrawn) The method of claim 20, wherein said dosage portions each individually include a number of doses in the range of 1 to 1 million.

22. (Withdrawn) The method of claim 20, wherein said infecting employ a viral preparation selected from the group consisting of a cell free preparation and a cell associated preparation.

23. (Withdrawn) The method of claim 20, wherein said cryoprotectant includes at least one material selected from the group consisting of glycerol, DMSO, and sugars.

24. (Withdrawn) The method of claim 20, wherein said desired viral yield is in the range of 0.001 to 1 PFU/cell.

25. (Withdrawn) The method of claim 20, wherein said temperature in the range of (+) 2 to (+8) degrees centigrade.

26. (Withdrawn) The method of claim 20, further comprising:

(f) passaging said individual cells belonging to said population with said desired viral yield as a means of increasing a size of said population.

27. (Withdrawn) The method of claim 20, further comprising:

(f) reducing a volume of said storage medium so that a desired number of cells per unit volume is achieved.

28. (Withdrawn) The method of claim 20, further comprising:

(f) drying said population of individual cells.

29. (Currently Amended) A method of ~~vaccination which employs an integrated viral complex, the method comprising~~ administering to a subject at least one dose of an amount of ~~an integrated viral complex~~ said vaccine sufficient to elicit an active immune response in a subject.

30. (Currently Amended) The method according to~~of~~ claim 29, wherein said subject is a member of an avian species.

31. (Currently Amended) The method according to ~~of~~ claim 29, wherein said vaccine ~~integrated viral complex includes~~ comprises of double stranded DNA virions.

32. (Currently Amended) The method according to ~~of~~ claim 31~~29~~, wherein said double stranded DNA virions are ~~double stranded DNA virions~~ herpes viruses.

33. (Currently Amended) The method according to ~~of~~ claim 32, wherein said ~~double stranded DNA virions belong to the~~ herpes virus is Marek's disease virus.~~es~~.

34. (Canceled)

35. (Currently Amended) The method according to ~~of~~ claim 29, wherein said administering ~~administration~~ is administered ~~conducted *in ovo*~~ to a chicken embryo in *ovo* at 18 days of incubation.~~o~~.

36. (Currently Amended)The method according to ~~of~~ claim 29, wherein said administering ~~administration~~ is ~~conducted~~ via IM injection, subcutaneous injection or by spraying methods to chicks at ~~from~~ 1 day of age.

37. (New) A live vaccine comprising a non-viable dried cell having a cell membrane and a viable virion contained within said cell.

38. (New) A pharmaceutical composition comprising said vaccine and stabilizing components, wherein said components are selected from a group consisting of carriers, cryoprotectants and excipients.